A deep-dive reference for pharma IP strategists, ANDA portfolio managers, formulation leads, and institutional investors tracking the generic drug sector. […]

How to diagnose the six most common grounds for pharmaceutical patent rejection — and the prosecution strategies that actually reverse

A deep-dive resource covering discovery frameworks, platform architectures, IP valuation, clinical case studies, ROI modeling, regulatory strategy, and the next

Part I: The Failing Commercial Architecture The commercial model that generated decades of reliable profit for large-cap pharmaceutical companies was

A deep-dive for pharmaceutical IP teams, R&D leads, and institutional investors on intellectual property architecture, regulatory pathways, exclusivity mechanics, and

Let’s start with a number that should make any pharmaceutical strategist put down their coffee: analysts project that emerging markets

Executive Summary Engaging a contract development and manufacturing organization (CDMO) has gone from tactical cost arbitrage to board-level strategic decision.

The launch price of a new medicine is the most durable, highest-stakes financial decision a pharmaceutical company makes. It is

The premise sounds straightforward enough: a blockbuster biologic loses patent protection, a competitor copies it at lower cost, patients save